Remove Marketing Remove Pharmaceutical Companies Remove Targeted Protein Degradation
article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

Thanks to technological breakthroughs, sponsors are developing more novel therapeutics for the CNS than ever – some targeting the most lethal conditions. The global market for CNS therapeutics was worth an estimated $144.3 Targeted protein degraders can easily cause off-target toxicity.

article thumbnail

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design

The Pharma Data

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed.

article thumbnail

Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration with Metrion Biosciences

The Pharma Data

This strategic technology collaboration is the latest in a series we have made with highly innovative companies in recent months designed to strengthen our platform and enhance our discovery and partnering opportunities. Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in Cambridge, UK.